A retrospective study assessing the real world survival and adverse events in patients treated with Palbociclib for metastatic Breast Cancer in Scotland
Latest Information Update: 25 Jan 2021
Price :
$35 *
At a glance
- Drugs Palbociclib (Primary) ; Aromatase inhibitors; Fulvestrant
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Jan 2021 New trial record
- 11 Dec 2020 Results presented at the 43rd Annual San Antonio Breast Cancer Symposium